Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

NCT05861778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Suspected Recurrent Renal Clear Cell Carcinoma
Recurrent Renal Cell Cancer

Interventions

DRUG: 89Zr-Girentuximab

Sponsor

Telix Pharmaceuticals (Innovations) Pty Limited

Collaborators

[object Object]